New study explores role of social responsibility in drug development
(Medical Xpress)—Though pharmaceutical companies that are developing "orphan drugs" do so mainly for the business potential, the companies also consider the effort as part of their corporate social responsibility, ...
Medications
Apr 01, 2013 |
not rated yet |
0
Even the poorest handheld umbrellas can block UV rays
(HealthDay)—Handheld umbrellas are effective at blocking ultraviolet radiation (UVR), according to a study published online March 20 in JAMA Dermatology.
Health
Mar 26, 2013 |
5 / 5 (2) |
0
High court weighs drug companies' generics policy
(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.
Medications
Mar 25, 2013 |
not rated yet |
0
AstraZeneca settles legal dispute with Watson (Update)
(AP)—Anglo-Swedish pharmaceutical company AstraZeneca has settled a patent dispute with Watson Laboratories, Inc., removing a threat against its top-selling cholesterol-control drug, Crestor.
Medications
Mar 25, 2013 |
not rated yet |
0
Malaria vaccine fails to work after four years
A new vaccine that has raised hopes of becoming a potent new tool in the battle against malaria seems to stop working in children after four years, according to research published Wednesday.
Medications
Mar 20, 2013 |
1 / 5 (1) |
0
New drug shows promise in ability to fight rare type of breast cancer
Researchers in the University of Delaware's Department of Biological Sciences are investigating a new drug that has shown positive results in early tests of its ability to fight a rare and aggressive form ...
Cancer
Mar 08, 2013 |
5 / 5 (3) |
0
Pharmaceutical companies: An $84 million marketing effort in the District of Columbia
Drug companies spent nearly $84 million marketing pharmaceuticals in the District of Columbia in 2011, including an outlay of nearly $19 million for gifts given to physicians, hospitals and other health care providers, according ...
Medications
Mar 01, 2013 |
not rated yet |
0
Deworming important for children's health, has limited impact on infection in wider communities
Although they have an important impact on children's health and education, school-based deworming programmes have a limited impact on the level of infection in the wider community, according to a mathematical modeling study ...
Diseases, Conditions, Syndromes
Feb 28, 2013 |
not rated yet |
0
FDA: Omontys injection pulled from market
(HealthDay)—Affymax Inc. of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited of Deerfield, Ill., have voluntarily recalled all lots of Omontys Injection, used to treat anemia in adult dialysis ...
Medications
Feb 26, 2013 |
not rated yet |
0
Natalizumab shows promise for teens with multiple sclerosis
(HealthDay)—Natalizumab may be safe in pediatric multiple sclerosis (MS) patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.
Neuroscience
Feb 22, 2013 |
5 / 5 (3) |
0
Antidepressants alone are not enough
We should reconsider how we use antidepressants more effectively. The latest studies have shown that antidepressants restore the capacity of certain areas of the brain to repair abnormal neural pathways. According to neuroscientist ...
Psychology & Psychiatry
Feb 22, 2013 |
5 / 5 (4) |
2
Researchers find new clue to clinical trial failures of MMP cancer therapies
Proposed cancer therapeutic drugs based on blocking the catalytic activities of matrix metalloproteinases (MMPs), which profoundly remodel the environment surrounding a breast cell, have performed poorly ...
Cancer
Feb 12, 2013 |
not rated yet |
0
Rivaroxaban found noninferior to enoxaparin in acutely ill
(HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has ...
Diseases, Conditions, Syndromes
Feb 07, 2013 |
not rated yet |
0
Danish Novo Nordisk profit surges
Danish pharmaceutical company Novo Nordisk A/S on Thursday reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide begin to approve its ...
Other
Jan 31, 2013 |
not rated yet |
0
Linagliptin: Once again, no proof of added benefit
Linagliptin (trade name Trajenta) has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. The assessment of the new dossier according to the German Act on the Reform of the Market ...
Medications
Jan 30, 2013 |
not rated yet |
0
